Nephron Pharmaceuticals Corporation

48 articles about Nephron Pharmaceuticals Corporation

• NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)

  3/11/2024

  NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply Important step toward goal of providing full suite of supply options, to to provide IV Ketamine to patients and clinics across the country, subject to board approval.

• NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression

  11/6/2023

  NRx Pharmaceuticals, Inc. and Nephron Pharmaceuticals, Inc. announced the signing of a development and manufacturing agreement to manufacture a presentation of ketamine suitable for treating suicidal depression, an urgent public health need.

• Nephron Announces Hiring of Key Executives

  10/24/2023

  Nephron Pharmaceuticals Corporation announced the new hiring of six key executives.

• Nephron, Partners Announce $350 Million Capital Raise for Future Growth

  9/15/2023

  Nephron Pharmaceuticals Corporation celebrated a successful $350 million capital raise – led by BlackRock Capital Investment Advisors, LLC and PNC Bank, National Association – to support future growth of the pharmaceutical manufacturer.

• Nephron Announces Julie Rameas as Chief Procurement Officer

  8/17/2023

  Nephron Pharmaceuticals Corporation today announced Julie Rameas as Chief Procurement Officer.

• Nephron Works to Resolve Nationwide Drug Shortage by Producing Vital Medications

  8/8/2023

  Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.

• Nephron Announces New President of 503B Outsourcing Facility

  6/8/2023

  Nephron Pharmaceuticals Corporation announced Christopher Fortier, PharmD, FASHP, CPEL, will join as President of its 503B Outsourcing Facility.

• Nephron To Produce 0.5% Albuterol 5 mL, Alleviating Nationwide Shortage

  5/31/2023

  Nephron Pharmaceuticals Corporation announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.

• Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products

  12/20/2022

  Sharps Technology, Inc., an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

• Nephron and Sharps Announce Manufacturing and Research Partnership

  11/10/2022

  Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. announced a brand new partnership focused on developing and sharing best practices in innovative manufacturing, product development, customer support, and quality as Nephron prepares to launch the InjectEZ component of expansion.

• Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. Announce Manufacturing and Research Partnership

  11/10/2022

  Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. announced a new partnership focused on developing and sharing best practices in innovative manufacturing, product development, customer support, and quality as Nephron prepares to launch the Company's InjectEZ component of expansion.

• Nephron Launches New Syringe Presentation

  1/31/2022

  Continuing to build on the momentum that comes with explosive growth, Nephron Pharmaceuticals Corporation today announced the launch of a brand new syringe presentation under the highly successful Nephron 503B Outsourcing Facility operation.

• 

  As Delta Variant Surges, More Biopharma Companies Mandate COVID-19 Vaccines

  8/19/2021

  Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections. 

• Nephron CEO Lou Kennedy, Governor McMaster Announce Launch of Nephron Nitrile

  7/15/2021

  During a celebration attended by strategic partners, business leaders and public officials, Nephron Pharmaceuticals Corporation CEO Lou Kennedy and Governor Henry McMaster announced the opening of Nephron Nitrile, a plant that will produce American-made, medical-grade nitrile gloves.

• New Nephron-Methapharm Collaboration Improves Health Outcomes for Respiratory Patients

  7/6/2020

  Nephron Pharmaceuticals Corporation, one of the fastest-growing pharmaceuticals companies in the country, today announced a new collaboration with Methapharm.

• Quality of Care Is a Key Component of the Right to Health

  12/5/2019

  Patients Quality Care Through Virtually Pain-Free Anesthetic: J-Tip Needle-Free Injector Delivering Nephron Pre-Filled Buffered Lidocaine improves the Quality of Care in Pain Management Settings   [05-December-2019]   IRVINE, Calif. , Dec. 5, 2019 /PRNewswire/ --  Quality Improvement Projects in Hospitals  are critical because they drive and improve outcomes for patient

• New Nephron Pharmaceuticals Corporation Partnership with National Medical Products Inc. Offers Patients Quality Care Through Virtually Pain-Free Anesthetic

  12/5/2019

   Nephron Pharmaceuticals Corporation today announced a new partnership with National Medical Products Inc. – developer of the J-Tip Needle Free Injector – that provides patients with an easy-to-use and virtually pain-free delivery of anesthetic medications prior to medical procedures.

• Lonza to Host New Webinar – “Paper to EBR in 9 Months: How a Strong Collaboration Leads to Project Success”

  10/28/2019

  Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform

• Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months – Case study to be presented at 2019 ISPE Annual Meeting

  10/3/2019

  Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting

• Nephron, UofSC researchers improving medication safety through automation

  9/6/2019

  Nephron Pharmaceuticals Corporation has joined forces with the University of South Carolina's College of Engineering and Computing and the College of Pharmacy to design and implement an automation process that significantly boosts production of pre-filled medication, reducing the physical burden on workers and increasing patient safety.